Sailon’s wholly-owned subsidiary obtains famotidine injection registration certificate
June 16, 2025
Source: drugdu
60
On June 12, Sailon (002898) announced that its wholly-owned subsidiary Hunan Sailon Pharmaceutical (Changsha) Co., Ltd. recently obtained the Drug Registration Certificate for Famotidine Injection approved and issued by the State Drug Administration. The drug is a Class 3 chemical drug, with an injection form and specifications of 1ml: 10mg and 2ml: 20mg. The registration certificate number is 2025S01758/2025S01757, and it is valid until June 9, 2030.
Famotidine injection is listed as a national basic medical insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)" Class A drugs, mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer. The approval of the drug will further enrich the company's preparation varieties, but the specific sales situation is still affected by a variety of internal and external environmental factors, and there is a certain degree of uncertainty.
In the first quarter of 2025, Sailon achieved revenue of 54.09 million yuan and net profit attributable to shareholders of the parent company was -1.04 million yuan.
https://finance.eastmoney.com/a/202506123429021183.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
- Rare, Recurrent, and Still a Challenge July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
